1569-16-0Relevant articles and documents
A mild synthesis of substituted 1,8-naphthyridines
Anderson, Edward C.,Sneddon, Helen F.,Hayes, Christopher J.
, p. 3050 - 3058 (2019)
A greener method for the synthesis of substituted 1,8-naphthyridines has been developed, which is supported by reaction metric analysis. Using 2-aminonicotinaldehyde as a starting material with a variety of carbonyl reaction partners, the Friedl?nder reac
Synthesis of 1,8-naphthyridine and BF2-based isomers and their application in fluorogenic sensing Cd2+
Liu, Xingjiang,Chen, Mingxing,Liu, Ziping,Yu, Mingming,Wei, Liuhe,Li, Zhanxian
, p. 658 - 663 (2014)
A series of isomers were synthesized and identified, two isomers of which were developed as the dual-channel fluorescent probe toward Cd2+. BF2 dissociates from the probe upon reaction with CdCl2, demonstrating a new approach for sensing Cd2+.
High-selectivity fibroblast growth factor receptor inhibitor and application
-
Paragraph 0087-0091, (2021/07/08)
The invention discloses a high-selectivity fibroblast growth factor receptor inhibitor and application, and particularly relates to a compound shown in a formula (I) or a pharmaceutically acceptable salt, a solvate, a geometric isomer, a stereoisomer, a tautomer and any mixture thereof. The compound shown in the formula (I) or the pharmaceutically acceptable salt, the solvate and the pharmaceutical composition thereof can be applied to prevention or treatment of diseases related to FGFR4 activity or overexpression, and can also be combined with other medicines to be used for treating various related diseases, especially for treating various cancers, wherein the cancers may be liver cancer, lung cancer, gastric cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, skin cancer, colon cancer, bile duct cancer, glioma or sarcoma.
PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS
-
Page/Page column 39, (2019/05/30)
The disclosure relates to compounds of formula I: Formula I which inhibit αv-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.